Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Boston Scientific Trading Volume Surges 92.55% to 178th Position Amid Legal Challenges

Market BriefMonday, May 12, 2025 8:00 pm ET

1min read

On May 12, 2025, Boston Scientific (BSX) saw a trading volume of 7.16 billion, marking a 92.55% increase from the previous day. This surge placed Boston Scientific at the 178th position in terms of trading volume for the day. The stock price of Boston Scientific (BSX) rose by 0.01%.

Boston Scientific is currently facing legal challenges related to its spinal cord stimulation (SCS) technologies. Patients have filed lawsuits alleging that the company made significant changes to its SCS systems without obtaining the necessary regulatory approvals. These changes are said to have affected the safety and effectiveness of the devices, leading to issues such as worsening pain and electric shocks for patients.

The lawsuits also include the FDA as a defendant, with plaintiffs claiming that the FDA approved changes to SCS devices through expedited channels without requiring new safety data. Boston Scientific has stated that it believes the suits lack legal merit. The company has not been served in any of the cases filed against it, and industry lawyers have cited preemption as a legal doctrine that could block these injury lawsuits.

One of the complaints against Boston Scientific targets its SCS product line, which includes the Precision system and its successors, such as Precision Plus, Precision Spectra, and Spectra WaveWriter. The complaint alleges that Boston Scientific aggressively marketed these systems as offering superior pain relief through innovative stimulation patterns. However, plaintiffs claim that these systems lacked independent premarket clinical testing to validate their long-term safety and effectiveness.

Boston Scientific submitted successive PMA supplements for its modifications, treating changes as minor updates to avoid heightened scrutiny and rigorous independent clinical evaluation. This regulatory strategy is said to have deprived physicians, patients, and the FDA of complete information necessary to evaluate the true risks associated with the modified devices. As a result, the Spectra WaveWriter and other successor systems entered the market and were widely implanted without sufficient scientific validation of their safety and effectiveness.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.